Donanemab
Medication for slowing the progression of Alzheimer's disease
📊 Rating
1 news mentions · 👍 0 likes · 👎 0 dislikes
📌 Topics
- Finance (1)
- Pharmaceuticals (1)
- Healthcare (1)
🏷️ Keywords
Eli Lilly (1) · BMO Capital (1) · Stock Market (1) · GLP-1 (1) · Kisunla (1) · Price Target (1) · Pharmaceuticals (1) · Earnings (1)
📖 Key Information
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. Donanemab was developed by Eli Lilly and Company.
The most common side effects include amyloid-related imaging abnormalities, which are brain hemorrhages and brain swelling, which can cause strokes, seizures, falls and trouble thinking.
📰 Related News (1)
🔗 Entity Intersection Graph
People and organizations frequently mentioned alongside Donanemab:
- 🌐 Stock market (1 shared articles)
- 👤 Eli Lilly (1 shared articles)